Biocryst Pharmaceuticals reported $615K in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Adamas Pharmaceuticals ADMS:US 576K 49K
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alnylam Pharmaceuticals ALNY:US $ 32.66M 2.41M
Biocryst Pharmaceuticals BCRX:US $ 0.62M 0.27M
Chugai Pharma 4519:JP Y 104194M 36135M
Daiichi Sankyo 4568:JP Y 87407M 2255M
Gilead Sciences GILD:US $ 1223M 167M
GlaxoSmithKline GSK:LN 2822M 303M
Glaxosmithkline GSK:US $ 2822M 303M
Intra Cellular Therapies ITCI:US $ 2M 0.04M
IONIS PHARMACEUT IONS:US $ 3M 0.04M
Karyopharm Therapeutics KPTI:US $ 589K 549K
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Ptc Therapeutics PTCT:US $ 6.54M 0.82M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Sarepta Therapeutics SRPT:US $ 23.44M 3.93M
Ultragenyx Pharmaceutical RARE:US $ 4.18M 1.04M
Vertex Pharmaceuticals VRTX:US $ 236.51M 8.54M
YTE INCY:US $ 34.47M 1.84M
Zogenix ZGNX:US $ 1.29M 0.07M